Ascendis Pharma A (ASND) Equity Average (2017 - 2025)
Ascendis Pharma A (ASND) has disclosed Equity Average for 9 consecutive years, with -$151.2 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 12.15% to -$151.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$151.2 million through Dec 2025, down 12.15% year-over-year, with the annual reading at -$151.2 million for FY2025, 12.15% down from the prior year.
- Equity Average hit -$151.2 million in Q4 2025 for Ascendis Pharma A, down from -$134.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $1.0 billion in Q4 2021 to a low of -$151.2 million in Q4 2025.
- Historically, Equity Average has averaged $283.0 million across 5 years, with a median of $56.0 million in 2023.
- Biggest five-year swings in Equity Average: rose 21.07% in 2021 and later crashed 340.99% in 2024.
- Year by year, Equity Average stood at $1.0 billion in 2021, then tumbled by 36.37% to $639.8 million in 2022, then tumbled by 91.25% to $56.0 million in 2023, then plummeted by 340.99% to -$134.9 million in 2024, then dropped by 12.15% to -$151.2 million in 2025.
- Business Quant data shows Equity Average for ASND at -$151.2 million in Q4 2025, -$134.9 million in Q4 2024, and $56.0 million in Q4 2023.